Sensitive to dabigatran — useful qualitative screen
Normal TT excludes significant dabigatran levels
💉 Coagulopathy Correction & Reversal
Agent
Indication
Dose/Notes
Fresh Frozen Plasma (FFP)
Warfarin overdose (no PCC available), factor deficiencies, massive transfusion
10–15 mL/kg; takes time to thaw — plan ahead
Prothrombin Complex Concentrate (PCC / Octaplex)
Urgent warfarin reversal; emergent surgery on warfarin
25–50 IU/kg depending on INR; faster than FFP; give with Vitamin K 10mg IV
Vitamin K (phytomenadione)
Warfarin reversal (non-urgent: oral; urgent: IV)
Oral: 1–5mg (full reversal 24–48h); IV: 5–10mg (risk of anaphylaxis — give slowly)
Protamine Sulphate
UFH reversal
1mg per 100 units UFH given in last 2–4h; max 50mg; only 60% reversal for LMWH
Idarucizumab (Praxbind)
Dabigatran reversal
5g IV (2 × 2.5g vials); complete reversal within minutes
Andexanet Alfa (Ondexxya)
Apixaban or rivaroxaban reversal
Low dose (400mg bolus + 480mg infusion) or high dose (800mg + 960mg); check last dose & timing
Tranexamic Acid
Adjunct for major bleeding on any anticoagulant
1g IV over 10 min, repeat at 8h if needed; anti-fibrinolytic
CAUTION: PCC is thrombogenic — use minimum effective dose. Do not use activated PCC (FEIBA) for DOAC reversal unless andexanet/idarucizumab unavailable.
⚠ Hypercoagulable States Overview
Inherited Thrombophilia
Factor V Leiden — most common; APC resistance
Prothrombin G20210A mutation
Protein C deficiency — warfarin skin necrosis risk at initiation
Protein S deficiency
AT-III deficiency — heparin resistance; may need AT-III concentrate
Malignancy — cancer-associated thrombosis; LMWH or DOAC (rivaroxaban/edoxaban) preferred over warfarin
Myeloproliferative disorders
Immobility, surgery, pregnancy, OCP
Nursing note: Do NOT check thrombophilia screen while patient is on anticoagulation — results will be invalid. Test after completing therapy or >3 months off warfarin.
🎯 INR Target Ranges by Indication
Indication
Target INR
Notes
Atrial Fibrillation (AF)
2.0–3.0
CHA₂DS₂-VASc score guides initiation; DOACs now preferred in most cases
VTE Treatment (DVT/PE)
2.0–3.0
3–6 months for provoked; lifelong if unprovoked or recurrent
Triple-positive APS: higher targets; warfarin superior to DOACs
Recurrent VTE on warfarin
2.5–3.5
Consider thrombophilia screen
⚙ Warfarin Initiation
Standard Initiation
Start 5mg daily in most adults
Check INR at day 3–4 and adjust
Loading doses (10mg) — rarely used; risk of supratherapeutic INR
Achieve stable INR within 5–7 days typically
Time to therapeutic effect: 3–5 days (protein C falls first → pro-thrombotic window; cover with heparin for mechanical valves/high-risk AF)
Reduced Starting Dose (2–3mg)
Age >70 years
Low body weight (<50kg)
Liver disease / elevated bilirubin
Heart failure (hepatic congestion)
Malnutrition / poor oral intake
Drug interactions already present
East Asian ancestry (CYP2C9 variants — more sensitive)
📅 INR Monitoring Frequency
Phase
Frequency
Rationale
Initiation / dose change
Daily or every 2 days until INR in range × 2
Rapid fluctuation during loading
Recently stable (<1 month)
Weekly
Confirm stability
Stable (>1 month, consistent diet/drugs)
Every 4–6 weeks
Routine monitoring
Very stable (>3 months, TTR >75%)
Every 8–12 weeks
Good evidence of stability
After illness / new drug / dietary change
Within 1 week
Interaction risk
Ramadan / major dietary change
Check within 1–2 weeks
Diet composition changes
TTR (Time in Therapeutic Range): Target >70%. If TTR <65% for 6 months despite good adherence — consider switching to DOAC.
📈 Dose Adjustment Algorithms
INR Below Range (sub-therapeutic)
INR
Action
1.5–1.9 (target 2–3)
Increase weekly dose by 10–15%; recheck in 1 week
<1.5 (target 2–3)
Increase weekly dose by 15–20%; consider supplemental dose; recheck in 5–7 days
<2.0 (target 2.5–3.5)
Increase 10–15%; recheck in 1 week
INR Above Range (supratherapeutic)
INR
Action
3.1–3.9 (target 2–3)
Reduce weekly dose by 10–15%; recheck in 1–2 weeks
4.0–4.9, no bleeding
Omit 1–2 doses; reduce weekly dose by 15–20%; recheck in 3–5 days
5.0–8.0, no significant bleeding
Omit doses; consider vitamin K 1–2.5mg oral; recheck in 24h
>8.0 or any major bleeding
STOP warfarin; vitamin K 5–10mg IV; PCC if urgent reversal needed; seek senior review
Important: Always adjust the weekly dose, not daily dose. Small adjustments (10–20%) prevent oscillation. Avoid "chasing" the INR with frequent large changes.
💊 Drug Interactions
Drugs that RAISE INR (potentiate warfarin)
Amiodarone — potent; INR rises over weeks; reduce warfarin by 30–50%
Azithromycin, metronidazole — common GCC antibiotics
Ciprofloxacin — moderate interaction
Statins (fluvastatin most; rosuvastatin moderate)
NSAIDs — displace from protein binding + GI risk
Omeprazole — mild CYP2C19 inhibition
Alcohol (acute)
Drugs that LOWER INR (reduce warfarin effect)
Rifampicin — potent CYP inducer; may need to double warfarin dose
Carbamazepine, phenytoin, phenobarbitone
St John's Wort — common herbal use in GCC
Nafcillin
Alcohol (chronic)
Avocado, high-fat meal (absorption)
Dietary Vitamin K
Consistency is key — patients should maintain steady vitamin K intake. Advise not to avoid greens entirely — advise consistent weekly intake. Sudden high-spinach/kale weeks lower INR; fasting raises INR.
⚠ Warfarin in Special Situations
Pregnancy
CONTRAINDICATED in first trimester (weeks 6–12): warfarin embryopathy (nasal hypoplasia, stippled epiphyses). Also avoid near term (weeks 36+): fetal haemorrhage and difficult reversal in neonates. Use LMWH throughout pregnancy or switch to warfarin in 2nd trimester ONLY if mechanical valve (high-risk thrombosis outweighs risk).
Liver Disease
Already have prolonged INR — monitoring unreliable
Start very low dose; frequent monitoring
Consider DOAC if no portal hypertension / varices
Elderly Patients
Falls risk — not an absolute contraindication; discuss risk vs benefit
More sensitive to warfarin; start 2mg
More drug interactions (polypharmacy)
DOACs (especially apixaban) may be preferable
💉 DOAC Comparison Overview
Drug
Target
Dosing (AF)
Renal Excretion
Reversal Agent
Dabigatran (Pradaxa)
Direct IIa (thrombin)
150mg BD (110mg BD if age >80/high bleed risk)
80%
Idarucizumab 5g IV
Apixaban (Eliquis)
Direct Xa
5mg BD (2.5mg BD if ≥2: age>80/wt<60/Cr>133)
27%
Andexanet alfa
Rivaroxaban (Xarelto)
Direct Xa
20mg OD with evening meal
33%
Andexanet alfa
Edoxaban (Lixiana)
Direct Xa
60mg OD (30mg if CrCl 15–50/wt<60/P-gp inhibitor)
50%
Andexanet alfa (off-label)
⚙ DOAC Renal Failure Cut-offs
Drug
Caution
Reduce Dose
AVOID / Contraindicated
Dabigatran
CrCl 30–50
110mg BD if CrCl 30–50 + bleed risk
CrCl <30
Apixaban
CrCl <50 with age/weight criteria
2.5mg BD (dose reduction formula)
CrCl <15 (limited data)
Rivaroxaban
CrCl 30–49
15mg OD for AF if CrCl 15–49
CrCl <15
Edoxaban
CrCl >95 mL/min (reduced efficacy!)
30mg OD if CrCl 15–50
CrCl <15
Edoxaban paradox: Avoid in CrCl >95 mL/min — rapid clearance reduces plasma levels and may increase stroke risk vs warfarin. Use alternative DOAC.
📆 Individual DOAC Profiles
Dabigatran (Pradaxa)
Only direct thrombin inhibitor DOAC
GI side effects common (dyspepsia in 10%); take with food or proton pump inhibitor
Capsule must NOT be broken/chewed — enteric coating important
Higher GI bleeding rate vs warfarin (though lower intracranial haemorrhage)
Dialysable — option in overdose
Substrate of P-glycoprotein (P-gp): verapamil, amiodarone, dronedarone increase levels
Apixaban (Eliquis)
Twice daily; least renal excretion of all DOACs → safest in CKD
Best bleeding profile in elderly patients (ARISTOTLE trial)
GI bleeding similar to warfarin (better than dabigatran/rivaroxaban)
Can be crushed and mixed with water/applesauce for NG tube administration
Preferred DOAC in most GCC guidelines for AF in elderly/CKD patients
Rivaroxaban (Xarelto)
Must be taken with the evening meal — absorption is food-dependent (bioavailability drops from 66% to <33% if fasted)
Once daily — convenience advantage
Higher GI bleeding rate than warfarin and apixaban
Available in 2.5mg dose for CAD/PAD (vascular protection with aspirin)
Substrate of CYP3A4 and P-gp — avoid with azole antifungals/HIV protease inhibitors
Edoxaban (Lixiana)
Once daily; approved for AF and VTE treatment
VTE: must be preceded by 5–10 days parenteral anticoagulation (heparin run-in)
Reduce to 30mg OD if: CrCl 15–50, weight ≤60kg, or P-gp inhibitor co-administered
🔄 DOAC vs Warfarin — Key Trial Evidence
Outcome
Dabigatran
Apixaban
Rivaroxaban
Edoxaban
Stroke / systemic embolism
Non-inferior / superior (150mg)
Superior
Non-inferior
Non-inferior
Major bleeding
Similar (110mg lower)
Significantly lower
Similar
Significantly lower
Intracranial haemorrhage
All DOACs significantly better
All DOACs significantly better
All DOACs significantly better
All DOACs significantly better
GI bleeding
Worse vs warfarin
Similar to warfarin
Worse vs warfarin
Similar (60mg worse, 30mg similar)
Mortality
Lower (150mg)
Lower
Similar
Lower
🔄 Switching Between Anticoagulants
Switch
Method
Warfarin → DOAC
Start DOAC when INR <2.0 (for most DOACs). For rivaroxaban/edoxaban: start when INR <3.0
DOAC → Warfarin
Continue DOAC + start warfarin; check INR just before next DOAC dose. Stop DOAC when INR ≥2.0 on 2 consecutive days
UFH infusion → DOAC
Stop infusion; start DOAC immediately (no gap needed)
LMWH → DOAC
Start DOAC at time of next scheduled LMWH dose (do not give both)
DOAC → UFH
Start UFH at next scheduled DOAC dose time
Warfarin → UFH/LMWH (bridging)
Start when INR falls below 2.0; stop 4–6h before procedure
Standard Protocol (therapeutic anticoagulation):
Bolus: 80 units/kg IV (max 10,000 units)
Infusion: 18 units/kg/h (max 1,500 units/h initially)
Check aPTT 6 hours after any rate change; target 60–100 seconds
aPTT-Guided Adjustment
aPTT (seconds)
Action
Recheck
<40
Bolus 80 units/kg; increase infusion by 4 units/kg/h
6 hours
40–59
Bolus 40 units/kg; increase infusion by 2 units/kg/h
6 hours
60–100 (target)
No change
Next morning (or 6h if recently adjusted)
101–120
Decrease infusion by 2 units/kg/h; no bolus
6 hours
>120
HOLD infusion 30–60 min; decrease by 3 units/kg/h; reassess
6 hours after restart
Monitor: Platelet count at baseline and every 2–3 days for first 14 days to detect HIT. Daily aPTT until stable, then every 24h.
💊 LMWH Dosing Reference
Enoxaparin (Clexane) — most commonly used in GCC
Indication
Dose
Route
Notes
VTE Prophylaxis (medical)
40mg OD
SC
Reduce to 20mg OD if CrCl <30
VTE Prophylaxis (surgical)
40mg OD (start 12h pre-op or 12h post-op)
SC
High-risk: consider 40mg BD or UFH
VTE Treatment (BD dosing)
1mg/kg BD
SC
Preferred in most patients
VTE Treatment (OD dosing)
1.5mg/kg OD
SC
Avoid OD in pregnancy/obesity/renal failure
ACS (NSTEMI/UA)
1mg/kg BD (or 0.75mg/kg BD if age >75)
SC
Max 7 days; renal dose if CrCl <30
Renal failure (CrCl <30)
1mg/kg OD (therapeutic)
SC
Monitor anti-Xa; consider UFH instead
Morbid obesity (BMI >40)
1mg/kg BD; max 150mg per dose
SC
Monitor anti-Xa levels; dose cap controversial
Anti-Xa Monitoring for LMWH
Sample 4 hours after 3rd or 4th dose (steady state). Target levels:
Therapeutic BD dosing: 0.6–1.0 IU/mL
Therapeutic OD dosing: 1.0–2.0 IU/mL
Prophylactic: 0.2–0.4 IU/mL
Routine anti-Xa monitoring NOT recommended in normal-weight patients with normal renal function — only monitor in: pregnancy, renal failure (CrCl <30–50), BMI >40, extremes of weight, recurrent VTE on LMWH.
⚠ Heparin-Induced Thrombocytopaenia (HIT)
HIT is a life-threatening prothrombotic disorder — NOT just low platelets. Stop all heparin immediately if HIT suspected (moderate or high probability). Risk: UFH > LMWH. Avoid platelet transfusions.
4T Score
Criterion
2 Points
1 Point
0 Points
Thrombocytopaenia
>50% fall; nadir ≥20×10⁹
30–50% fall; nadir 10–19×10⁹
<30% fall; nadir <10×10⁹
Timing (platelet fall onset)
Days 5–10; or ≤1 day if heparin in past 30 days
>10 days; or ≤1 day (heparin 30–100 days ago)
≤4 days without recent heparin
Thrombosis
New proven thrombosis; skin necrosis; acute systemic reaction after bolus
HIT unlikely; continue heparin; consider other causes
4–5
Moderate
STOP heparin; send HIT antibody (ELISA); start non-heparin anticoagulant
6–8
High
STOP all heparin immediately; start alternative anticoagulant; urgent haematology review
Alternative Anticoagulants in HIT
Agent
Mechanism
Notes
Argatroban
Direct thrombin inhibitor (IV)
Hepatically metabolised — preferred in renal failure; monitor aPTT
Danaparoid
Anti-Xa heparinoid
Cross-reactivity with HIT antibody <10%; monitor anti-Xa
Fondaparinux
Selective anti-Xa
No cross-reactivity; not licensed for HIT but widely used; avoid if CrCl <30
DOACs (argatroban bridge)
Oral
Transition to rivaroxaban/apixaban after platelet recovery (>150×10⁹)
Warfarin is CONTRAINDICATED in acute HIT — causes venous limb gangrene by depleting protein C before thrombin inhibition catches up. Only introduce warfarin after platelet recovery and adequate alternative anticoagulation.
💉 Protamine Reversal of Heparin
UFH Reversal
Protamine 1mg per 100 units UFH received in last 2–4 hours
Maximum single dose: 50mg
Give IV slowly over 10 minutes — rapid injection causes hypotension/bradycardia
Check aPTT 15 minutes after; repeat if needed
LMWH Reversal (Partial)
Protamine 1mg per 1mg enoxaparin (if given <8h ago)
Only ~60% reversal of anti-Xa activity (longer chain polysaccharides)
Consider second dose (0.5mg/mg) if 8–12h ago
If >12 hours: limited benefit; consider recombinant factor VIIa in life-threatening bleeds
Protamine allergy risk: Higher in patients with fish allergy, prior protamine exposure, or vasectomy. Have resuscitation equipment available; slow infusion rate.
📋 Bridging Therapy — When to Bridge and When NOT to
Bridge WITH Heparin (LMWH/UFH)
Mechanical heart valves (any position)
Recent stroke/TIA <3 months
Recent VTE <3 months
Very high-risk AF (CHA₂DS₂-VASc >6 with prior stroke)
Recurrent stroke or embolism on warfarin
Do NOT Bridge (BRIDGE trial evidence)
Most AF patients (CHA₂DS₂-VASc 1–5) — BRIDGE trial showed equivalent clot risk with significantly more bleeding
Low/moderate VTE risk >12 months ago
Bioprosthetic heart valves
Low-risk procedures (colonoscopy, minor dental)
BRIDGE Trial (NEJM 2015): Bridging with LMWH in AF patients undergoing elective procedures did NOT reduce arterial thromboembolism but significantly increased major bleeding. Changed international guidelines — most AF patients do NOT require bridging.
⚙ Warfarin Periprocedural Management
Step
Timing
Action
Stop warfarin
5 days before procedure
INR typically normalises in 5 days; some patients need longer
Check INR
Day before procedure
Target INR <1.5 for most surgeries; <1.2 for neurosurgery/ophthalmology
If INR still elevated day before
Day before
Vitamin K 1–2mg oral (bridge the gap)
Restart warfarin
Evening of surgery or next morning
If haemostasis achieved; usual dose
INR check post-restart
3–5 days post-op
Confirm therapeutic; resume normal monitoring schedule
⚙ DOAC Periprocedural Management
DOAC
Low Bleed Risk Procedure
High Bleed Risk (or eGFR <50)
Restart Post-op
Apixaban / Rivaroxaban
Stop 24h before
Stop 48h before
24–48h post-op when haemostasis achieved
Dabigatran (eGFR ≥50)
Stop 24h before
Stop 48h before
24–48h post-op
Dabigatran (eGFR <50)
Stop 48h before
Stop 72–96h before
48–72h post-op
Edoxaban
Stop 24h before
Stop 48h before
24–48h post-op
Key principle: DOACs have short half-lives — no need for bridging in most cases. Simply time the last dose appropriately. No INR/anti-Xa check needed before routine procedures.
High-risk procedures (48h+ hold)
Major cardiac/vascular surgery
Neurosurgery / spinal surgery
Major orthopaedic surgery (hip/knee replacement)
Urological procedures (TURP, nephrectomy)
Major abdominal/pelvic surgery
🏳 Dental Procedures on Anticoagulation
General principle: For most dental procedures (extraction 1–3 teeth, scaling, simple restoration), do NOT routinely stop anticoagulation. Use local haemostatic measures: oxidised cellulose (Surgicel), tranexamic acid mouthwash, gelatin sponge, suturing.
Procedure
Recommendation
Simple extraction (1–3 teeth), scaling
Continue anticoagulation; local haemostatic measures
Spinal haematoma is a rare but devastating complication. If patient develops back pain or neurological deficit after neuraxial procedure — this is a neurosurgical emergency. Urgent MRI and decompression within 6–8 hours.
🌍 GCC Epidemiology & AF Burden
The GCC population faces a unique combination of cardiovascular risk factors driving high AF prevalence:
Risk Factor Profile
High rates of type 2 diabetes (GCC among world's highest)
Obesity — BMI >30 prevalent in 35–40% of GCC nationals
Hypertension — often uncontrolled
Sedentary lifestyle; metabolic syndrome
Ageing national population — over-65s growing rapidly
High prevalence of structural heart disease (rheumatic in older patients)
GCC-Specific Anticoagulation Challenges
Warfarin adherence: inconsistent diet (variable vitamin K intake), busy work schedules, Ramadan fasting
INR monitoring access: varies between countries; urban vs rural
Polypharmacy: traditional herbal medicines (common in GCC) may interact
Language barriers in expatriate population
Travel between GCC countries — different pharmacy access
🕑 Ramadan and Anticoagulation
Ramadan consideration: Approximately 1 month of altered eating patterns, hydration, sleep, and medication timing. Requires proactive anticoagulation management planning.
Warfarin during Ramadan
Dietary vitamin K intake may change significantly (dietary pattern shift to post-iftar foods)
Fasting can alter hepatic metabolism
Dehydration increases renal drug clearance
Action: Check INR 1–2 weeks before Ramadan; check again at 2 weeks into Ramadan; counsel on food consistency
Continue warfarin at same time daily (before suhoor or iftar — advise consistency)
Rivaroxaban OD:must be taken with a meal — shift to iftar (main evening meal)
Dabigatran BD: suhoor + iftar with small amount of food/water
Edoxaban OD: shift to iftar
DOACs generally more straightforward than warfarin during Ramadan
Nurse-led Ramadan counselling session recommended for all anticoagulated patients 2–4 weeks before Ramadan. Document dose timing plan in the patient record.
📋 Self-Monitoring INR — CoaguChek XS
Available in GCC
The CoaguChek XS point-of-care INR device is available in major GCC pharmacies (Saudi Arabia, UAE, Qatar, Bahrain, Kuwait, Oman). Enables patient self-testing at home.
Feature
Detail
Sample
Fingerprick whole blood (8 µL)
Range
INR 0.8–8.0
Accuracy
±0.5 INR units (well within clinical acceptability)
High patient-to-physician ratio; limited dedicated anticoagulation time
Pharmacist-led anticoagulation clinic
King Faisal Specialist Hospital (Riyadh), HMC Qatar, NMC (UAE)
Evidence-based; higher TTR; pharmacists have prescribing authority in some GCC countries
Nurse-led anticoagulation clinic
Growing — SKMC Abu Dhabi, Cleveland Clinic Abu Dhabi, some MOH clinics (UAE)
Nurse specialist role expanding; requires formal competency framework
Telemedicine INR management
Post-COVID expansion across GCC
Patient uses CoaguChek at home; calls/apps results to nurse/pharmacist
Evidence: Dedicated anticoagulation clinics (pharmacist or nurse-led) achieve significantly higher TTR (70–80%) vs ad hoc management (50–60%) in GCC populations.
💊 Reversal Agent Availability in GCC
Agent
GCC Availability
Notes
Vitamin K (oral/IV)
All GCC countries — widely available
Standard pharmacies and all hospitals
FFP / PCC (Octaplex, Beriplex)
All major hospital blood banks
PCC increasingly preferred over FFP for warfarin reversal
Protamine sulphate
Available in all cardiac/surgical centres
Cardiac surgery standard; ensure availability in wards using UFH
Idarucizumab (Praxbind)
Available in major tertiary centres (KFSH Riyadh, HMC Doha, SKMC/CCAD Abu Dhabi, JCI-accredited hospitals)
Expensive; check local formulary. 5g = 2 vials of 2.5g
Andexanet alfa (Ondexxya)
Limited availability — some tertiary centres in UAE and Saudi; not universally stocked
Very expensive (~$25,000 USD per treatment course); some centres use 4-factor PCC off-label for DOAC reversal
4-factor PCC (off-label for DOACs)
Widely available
Used as pragmatic alternative to andexanet in centres without andexanet; 50 IU/kg for rivaroxaban/apixaban major bleed
Nursing action: Know your local formulary. Before starting a DOAC, confirm reversal agent availability at your facility. Document in patient's record and include in discharge education.
📅 DOAC Prescribing Trends in GCC
The transition from warfarin to DOACs has accelerated significantly in GCC over the past 5–8 years:
By 2024, apixaban and rivaroxaban are the most prescribed anticoagulants for AF in most GCC centres